Burrows Scott L 4
4 · Spyre Therapeutics, Inc. · Filed Mar 3, 2026
Insider Transaction Report
Form 4
Burrows Scott L
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-03$14.50/sh+2,500$36,250→ 100,494 total - Sale
Common Stock
[F1][F2]2026-03-03$40.56/sh−2,300$93,288→ 98,194 total - Sale
Common Stock
[F1][F3][F4]2026-03-03$41.66/sh−200$8,332→ 97,994 total - Exercise/Conversion
Stock Option (Right to Buy)
[F1][F5]2026-03-03−2,500→ 402,357 totalExercise: $14.50Exp: 2033-09-01→ Common Stock (2,500 underlying)
Footnotes (5)
- [F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2025.
- [F2]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $40.17 to $41.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]The price reported above is a weighted average price. The shares were sold in multiple transactions at prices ranging from $41.55 to $41.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F4]Includes 67,476 restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting, one share of Common Stock. The RSUs vest in two equal installments on each of September 1, 2026 and 2027, subject to the Reporting Person's continued employment with the Issuer.
- [F5]This option represents a right to purchase 404,857 shares of the Issuer's common stock (which have been adjusted to reflect the Issuer's 1-for-25 reverse stock split on September 8, 2023), one quarter of which vested and became exercisable on September 1, 2024, with the remaining three quarters vesting in monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer.
Signature
/s/ Heidy King-Jones, as Attorney-in-Fact|2026-03-03